Navigation Links
Avanir Pharmaceuticals to Present at Three Conferences in March
Date:2/23/2011

ALISO VIEJO, Calif., Feb. 23, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced that company management will present an overview of the company at the following conferences in March.

  • Citi 2011 Global Healthcare Conference
    • Location: Hilton New York, New York, NY
    • Presentation date: Tuesday March 1, 2011
    • Presentation time: 8:00am ET

  • Cowen & Company Healthcare Conference
    • Location: Boston Marriott, Boston, MA
    • Presentation date: Tuesday March 8, 2011
    • Presentation time: 8:45am ET

  • 2011 Roth OC Growth Conference
    • Location: The Ritz Carlton, Laguna Niguel, CA
    • Presentation date: Monday March 14, 2011
    • Presentation time: 5:00pm PT

A live webcast and 30-day archive of these presentations will be available at http://www.avanir.com.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR™ and NUEDEXTA™ are trademarks owned by Avanir Pharmaceuticals, Inc.

©2011 Avanir Pharmaceuticals, Inc. All Rights Reserved.


'/>"/>
SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
8. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
9. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb ... in ambulances and other transport vehicles, an advanced and portable UV ... personnel for the first time. In order to ... these deadly pathogens, West Palm Beach Fire ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
(Date:4/21/2014)... EAST LANSING, Mich. --- The most effective way ... at the start and keep them from growing. ... the Journal of Biological Chemistry , shows ... clumping, or aggregating, the first step of neurological ... Huntington,s disease. , The results are pushing the ...
(Date:4/20/2014)... A single type of cell in the lining ... invasive bladder cancer, according to researchers at the Stanford ... mice, is the first to pinpoint the normal cell ... It,s also the first to show that most bladder ... one cell, and explains why many human bladder cancers ...
(Date:4/18/2014)... a discovery that turns 160 years of neuroanatomy on ... known to be essential for the fast transmission of ... as ubiquitous as thought, according to a new work ... Cell Institute (HSCI) and the University,s Department of Stem ... Lichtman, of Harvard,s Department of Molecular and Cellular Biology. ...
(Date:4/18/2014)... made a brain-related discovery that could revolutionize doctors, ... discovery opens up the possibility that environmental and/or ... brain activity that the researchers have identified as ... of Neuroscience has just published a paper ... professor of psychology and his doctoral student John ...
(Date:4/17/2014)... PHILADELPHIA The presence of chronic inflammation in ... aggressive, prostate cancer, and this association was found ... levels, according to a study published in ... of the American Association for Cancer Research. , ... some participants of the placebo arm of the ...
Breaking Medicine News(10 mins):Health News:MSU physicists push new Parkinson's treatment toward clinical trials 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... for Cryopreservation of Cell-Based ... Melanoma Therapy, ... BLFS), a leading developer and marketer of,proprietary hypothermic storage and cryopreservation ... the,adoption of its products in the cellular therapy and cord blood ...
... Reesman, RN, Executive,Director, Passport Health Colorado, says far too ... types, leave,home without taking the basic steps she suggests ... into their health as they do into their,destination choice, ... 1) Get advice from a travel health professional. ...
... new standards, LENEXA, Kan., Mar. 26 ... of ClosedLoop(TM) clinical systems for,blood and medication management, ... Transfusion software for hospital,blood banks and LifeTrak(R) software ... global blood labeling standards being required in the,United ...
... 2008 Resources for Voters on Health Care and,Social ... Academy of,Actuaries said the most recent Medicare trustees, ... long-term financing issues.,According to the program,s trustees, Medicare,s ... taxes, and Medicare must,rely also on interest accrued ...
... Spheris, a leading global,outsource provider of clinical documentation technology ... months ended December 31, 2007., Financial Highlights-Fourth Quarter ... of 2007 were $48.6 million compared,with $51.4 million in ... net revenues during the fourth quarter of 2007 from ...
... March 26 FluoroPharma Inc., a company,developing ... Emission,Tomography (PET) market, announced that it has ... Hospital (MGH) for the development and,commercialization of ... (AD). The licensed technologies, which were co-developed ...
Cached Medicine News:Health News:BioLife Solutions Expands Presence in Cell Therapy and Cord Blood Banking Market Segments 2Health News:BioLife Solutions Expands Presence in Cell Therapy and Cord Blood Banking Market Segments 3Health News:The Top Ten Health Tips for International Travel 2Health News:ISBT 128 Labeling Implementation Date Looms for Blood Centers 2Health News:ISBT 128 Labeling Implementation Date Looms for Blood Centers 3Health News:Medicare Trustees' Report Highlights Need for Reform 2Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 2Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 3Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 4Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 5Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 6Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 7Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 8Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 9Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 10Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 11Health News:FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimer's Disease (AD) 2
... the quantitative determination of Immunoglobulin E ... atopic allergic diseases such as atopic ... been shown to exhibit increased total,immunoglobulin ... is also known as the,reagenic antibody. ...
...
...
...
Medicine Products: